Collateral flow, even when developed after acute myocardial infarction (AMI), prevents the progressive left ventricular dilation and remodeling after AMI. independent of infarct size reduction. The mechanisms underlying this situation are unknown. The purpose of this study was to examine the hypothesis that collateral flow influences the collagen volume fraction in the necrotic area. We studied ten mongrel dogs with AMI. The dogs were sacrificed five days later. The hearts were arrested in diastole, perfusion fixed, and sliced. Sections from each slice were taken from the center of the infarct zone, and stained with hematoxylin and eosin or picrosirius red. Collagen analysis was performed using polarized light microscopy. Using a random sampling morphometric technique, the relative density of collagen, was calCUlated. To confirm the results from morphometry fresh transmural myocardial tissue samples were also taken from the center of the infarct zone, and processed for measurement of hydroxiproline content (/Lg/mg dry tissue weight). Myocardial blood flow was measured with 99mTc labeled microspheres(10 /Lm). Collagen deposition was analyzed in relation to baseline variables including the anatomic area at risk, necrosis, collateral blood flow and hemodynamic determinants of myocardial metabolic demand (heart rate, blood pressure, rate pressure product). Stepwise multivariate regression analysis showed that only collateral blood flow contributed to the model predicting an increase in myocardial collagen content (r 2 = 0.89) P = 0.01. In conclusion, we found that after a myocardial infarction a rich collateral flow to the necrotic area is associated with an increase in the collagen content. This is probably one of the reasons why after AMI, collateral flow has a positive influence on ventricular remodeling, independent of infarct size reduction.
Adhesion between neutrophils and endothelial cells has been demonstrated to be a requisite event for neutrophil migration into injured tissue. The selectins mediate transient, reversible adhesion of neutrophils to endothelial cells after ischemia reperfusion, and thus may facilitate neutrophil-mediated tissue damage. We tested the hypothesis that administration of an oligosaccharide analog of Sialyl Lewis-X (CY 1503). a known counter receptor for the selectins, may limit infarct size when given during coronary thrombolysis. A thrombus was formed in the circumflex (Cx) coronary artery of 20 dogs using electrolytic injury. Coronary blood flow was monitored with a Doppler flow probe, and continuous ECG monitoring was performed. After at least 1 hour of occlusion (mean ± SO; 80 ± 20 min). thrombolysis was induced in a random fashion with t-PA (1 mglkg) given over 20 min with either placebo (ñ 10) or CY 1503 given as a single bolus of 40 mg/kg (n = 10). At the onset of reflow each dog received a continuous infusion of t-PA (20 /Lg/kg/min) to maintain reperfusion for 60 minutes. The heart was then explanted and perfused with Evan's blue and triphenyl tetrazolium chloride dyes to define the coronary distribution and regions of myocardial necrosis. Sections of myocardium from the area at risk were assayed for myeloperoxidase (MPO) content. an index of neutrophil infiltration. No hemodynamic or adverse effects were noted in the CY 1503 treated dogs. Infarct size, expressed as a percent of the area at risk was reduced by 68% in CY 1503 treated dogs (p = 0.007). MPO content in the ischemic Cx territory was also markedly reduced in the CY 1503 group (p = 0.02).
We conclude that inhibition of neutrophil-endothelial cell adhesion by CY 1503 reduces infarct size well beyond thrombolytic-mediated reperfusion. and is a highly attractive strategy for future clinical investigation. The presence of bundle branch block (BBB) in the admission ECG during acute MI has been recognized as a powerfUl prognostic factor. Occasional case reports have suggested that timely reperfusion of the infarct-related artery may revert the injury to the conduction system. However, the outcome of pts presenting with acute MI and BBB has not been scrutinized in the thrombolytic era. We compared all North American GUSTO-l patients who had BBB in the admission ECG (n = 420; 0.017%) with an equal number of GUSTO-l North American pts without BBB matched for age and Killip class at admission. One hundred and thirty-one pts presented with LBBB and 289 pts presented with RBBB (isolated RBBB: 133 pts; RBBB + LAH: 145 pts; RBBB + LPH: 11 ptsl Mean age was 68.3 and mean Killip class was 1.32 for both groups. Pts admitted with BBB had higher event rates for 30-day mortality 122% vs 10%; P = 0.003), asystole during hospitalization (18% vs 8%; P < 0.001). and need for pacing (22% vs 13%; p = 0.006) than their matched controls After adjusting for all additional baseline prognostic variables, BBB remained an independent predictor for 30-day mortality (p = 0.036; Odds Ratio~1.58; 95% CI = 103-2.43). 
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Group It has been hypothesized that PMN-mediated reperfusion (R) injury is triggered by increased expression of intracellular adhesion molecule 1, (ICAM-1). on the surface of the coronary endothelium follOWing ischemia and reperfusion which in turn triggers C018-mediated adhesion of circulating neutrophils (PMN) and subsequent postischemic inflammation. In order to evaluate the role of ICAM in the pathogensis of postischemic injury, experiments were performed in an isolated rat heart model perfused with isolated PMNs and plasma. The efficacy of a specific monoclonal antibody (MAb) against ICAM, IA-29 (Upjohn). was studied in hearts subjected to 20 min of global ischemia and 45 min of R. 3 x 10 7 PMNs and plasma were infused during the first 5 min of R, with or without IA-29 (20 mg/ml); N = 10/group. Contractile function and PMN retention were measured. This specific anti ICAM-l antibody markedly increased the recovery of contractile function and decreased PMN retention. These experiments demonstrate that a blocking antibody to ICAM-l can be effective in reducing PM N accumulation and subsequent PMN-mediated reperfusion injury. Thus, the use of a MAb against ICAM-l could be an effective therapeutic approach to prevent myocardial reperfusion injury.
Summary data of (%) recovery at 45 min are shown below
